Ignite Creation Date:
2025-12-26 @ 11:13 PM
Ignite Modification Date:
2025-12-26 @ 11:13 PM
Study NCT ID:
NCT01016912
Status:
COMPLETED
Last Update Posted:
2015-10-12
First Post:
2009-11-19
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-12
Start Date Type:
None
Primary Completion Date:
2010-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-09
Completion Date Type:
ACTUAL
First Submit Date:
2009-11-19
First Submit QC Date:
None
Study First Post Date:
2009-11-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2015-08-17
Results First Submit QC Date:
None
Results First Post Date:
2015-10-12
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-09-23
Last Update Post Date:
2015-10-12
Last Update Post Date Type:
ESTIMATED